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The search for genetic markers associated with low
or moderate risk for different disorders has been applied
for various multifactorial diseases to date, among them
psychiatric, neurological and cardiological diseases and
various types of cancer. The approach is of high scientific
importance as it may provide new insights into
pathomechanisms and interactions between functional
components of biological systems. This knowledge might
be the basis for the development of new therapeutic
targets and individualised prevention strategies.
Nevertheless, despite its importance for basic
research, testing for low/moderate risk markers in
routine diagnostics for accurate cancer risk prediction
as well as prevention, surveillance, and treatment
schemes does not seem feasible to us in the near future. 
Our understanding of the genetic basis of complex
diseases is still in its infancy and use of the data for
prevention and treatment will probably require much
more time and data than previously thought. At present,
the identification of SNPs and other types of genetic
variability precedes the clarification of their functional
relevance by far. One promising exception might be the
field of pharmacogenetics, where polymorphic variants
play an increasing role in medical practice. Based on
current knowledge, screening for low/moderate genetic
risk markers in sporadic tumours seems to be of limited
value in routine practice. This is also underscored by
several guidelines and recommendations of medical
associations such as the Statement on the Genetic
Diagnosis of Factors that Predispose to Multifactorial
Diseases of the German Society of Human Genetics.
The major concerns considered from different
perspectives can best be illustrated by comparison with
the major gene approach.
M Me ed di ic ca al l   c co on ns si id de er ra at ti io on ns s
The most important concern relates to basic
considerations. In monogenic hereditary cancer
syndromes (e.g. hereditary breast cancer, HNPCC,
FAP , etc.) you have a family history, a specific tumour
spectrum, an evident mode of inheritance, etc. In
these cases there is a defined (limited) number of
persons affected with a defined, high tumour risk due
to a highly penetrant mutation in a limited number of
genes. Due to the high predictive power regarding
disease manifestation, we consider that the search
for genetic factors in these families is straightforward
and helpful for predictive diagnostics, surveillance
and therapy.
In sporadic cancer – or families with a certain
unspecific clustering of tumours – many, if not numerous,
low/moderate risk variants will contribute to cancer risk.
Moreover, it is unknown to date whether the interaction
of individual markers is based on additive, multiplicative,
or epistatic effects. Even if all potential risk factors were
identified and correctly interpreted, the predictive value
for a given individual would still be limited. 
Although the heritability of common sporadic
cancers seems to be a substantial burden (estimates
range from 26 to 42%, for CRC e.g. around 35%),
several studies agree that probably 60-90% of the
common cancers can be explained by environmental
factors. Evidence for the predominant influence of
environmental factors comes from three directions: 
i)  twin studies where the rate of concordance in
monozygotic twins is generally less than 15%,
ii) migration studies,
iii) studies on the risk of a second primary cancer in
paired organs.
Based on these observations it seems to be impossible
to provide sufficient individual risk assessments on the
basis of low/moderate genetic risk factors alone [1, 2].
Assuming an optimal situation, all identified
low/moderate susceptibility variants together (e.g. an
SNP-based “risk profile”) may represent an important
risk factor beside e.g. environmental influences. However,
if dozens or hundreds of low/moderate risk markers are
known, a huge number of combinations and interactions
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leading to all imaginable degrees of risk values
throughout the population (maybe comparable to 
a Gaussian normal curve of distribution). It will be very
difficult to calculate and validate the tumour risk
conferred by each potential combination of variants,
delineate different risk groups (which might always be
arbitrary in a flowing risk model), and to develop
appropriate specific surveillance and prevention
strategies for all different risk groups, in particular due
to the low number of persons harbouring a certain risk
combination as well as compliance problems. Moreover,
the role of protective factors is difficult to assess, and
the influence of environmental or other non-genetic
factors is not considered at all by the low/moderate risk
genetic approach. Nowadays, the risk identified by e.g.
certain SNPs is just a statistical correlation that cannot
adequately predict the individual risk.
Anyway, to validate and recommend individualised
prevention/surveillance protocols based on those
profiles, much longer term clinical studies on large
numbers of patients are needed. Even in late onset
monogenic disorders the identification of a highly
penetrant mutation in a healthy carrier does not often
allow accurate prediction of the course of future disease
(time at onset, spectrum of symptoms, complications,
etc), although we all realise that probably not all carriers
need the same kind and intensity of surveillance.
P Ps sy yc ch ho ol lo og gi ic ca al l   a an nd d   e et th hi ic ca al l   c co on ns si id de er ra at ti io on ns s
Molecular genetic tests in hereditary cancer
syndromes are applied to a target population that is
aware of its high tumour risk due to family history.
Therefore, ethical or psychosocial problems in this
context are mostly controllable, assuming that genetic
counselling is offered to the selected patients. Moreover,
you have “real facts” to explain to them, and can provide
a real help by predictive diagnostics and surveillance
for persons at risk and identified mutation carriers.
In contrast, the low/moderate cancer risk marker
approach implies broad genetic screening of the
general population (population screening) for
polymorphic variants in different genes, since there is
no other way to select the target population. Thus,
practical application will exhibit all the problems typical
for population screening: the people who might benefit
are healthy, have no family history of tumours and are
at (low) a priori life-time risk of developing any type of
cancer. As most people including physicians are 
not familiar with the correct  interpretation and
communication of risk figures, the test results are prone
to be misunderstood in both ways, a false positive or
false negative, leading to unfounded concerns or
unfounded reassurance. Since every person will carry
a few risk factors, the whole population might feel some
kind of illness or risk for something after being tested.
It will be a challenge to provide adequate genetic
counselling to the large number of tested individuals,
and to explain the complex risk figures and the
difference between statistical association and individual
risk. As a consequence, low/moderate risk gene
screening will create a lot of uncertainty and anxiety in
the population.
If it is accepted that patients with a relatively small risk
increase (compared to monogenic disorders) might
benefit from some kind of prevention/surveillance or
modifications of existing population screening
programmes, respectively, serious compliance problems
may occur. Even high risk groups (e.g. mutation carriers
for hereditary tumour syndromes) often do not perform
surveillance at the desired intensity; the acceptance of
less intensive surveillance for moderate risk prevention
might be worse. Also, the surveillance methods applied,
e.g. in hereditary tumour syndromes, are not free of
(serious) side effects and complications, and thus their
recommendation and intensity must always be balanced
against the level of potential benefit. The risk/benefit ratio
will only be sufficient in patients with a certain degree of
risk. As probably most surveillance recommendations
(e.g. gastrointestinal endoscopy) for low/moderate risks
are not validated adequately, over-protection of patients
accompanied by unnecessary side effects might be the
consequence. Partly, these problem might be more
relevant in hereditary tumour diseases and other
conditions where invasive techniques of surveillance are
applied compared to diseases where prevention strategies
are restricted to (harmless) changes in diet, etc.
E Ec co on no om mi ic c   c co on ns si id de er ra at ti io on ns s
This aspect includes not only the costs of molecular
diagnostics, but also the costs of clinical surveillance
programmes that follow for a given combination of low
risk markers. While the current, relatively high costs of
molecular diagnostics are expected to decrease due to
the introduction of new and cheaper technologies (e.g.
multiplex analysis of different variants), the costs for genetic
counselling and clinical management will largely increase.
It seems reasonable that almost every individual will have
at least a few low/moderate risk markers. This would result
in an increasing number of clinical surveillance
programmes. It is expected that our health systems will
manage the costs for molecular diagnostics and
surveillance that are actually applied to families with
hereditary cancer syndromes, but it would probably be
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substantially overloaded by the introduction of the
low/moderate genetic risk approach in routine practice.
L Le eg ga al l   c co on ns si id de er ra at ti io on ns s
If the low/moderate genetic risk marker approach
were broadly introduced to clinical practice, it is
expected that legal aspects would expand. For 
a general practitioner (and not only for them) it is
extremely difficult to understand the proper meaning
of the genetic test itself and of the clinical consequences
resulting from the test results. In order to avoid getting
into legal trouble, this approach may lead to over-
prevention by surveillance for each individual once the
screening is introduced to clinical practice. The
appropriate level of informed consent and pre-test
counselling as well as the group of health care
professionals who should be allowed to offer and
interpret the (population-based) genetic screening are
completely unknown to date. In any case, the broad
introduction of low/moderate genetic risk screening
will require new structures in health care systems.
C Co on nc cl lu us si io on ns s
The search for moderate genetic risk factors in
multifactorial disorders is of high scientific importance
as it may uncover important pathophysiological
pathways and lead to identification of markers or
combinations of markers that confer a significantly
increased (cancer) risk and thus may justify individualised
modifications of existing surveillance and treatment
protocols. Therefore, it is appropriate to continue this
approach on a research basis. However, although
identification of certain risk profiles in the future may
contribute to individual risk calculation in addition to
traditional risk factors, the current state of knowledge
does not justify screening for low/moderate risk markers
in clinical practice, mainly based on medical reasons,
but also because of ethical, psychosocial, economic
and legal reflections. Some of these considerations are
of more general relevance, while others may change in
the future and should be reconsidered as soon as new
hard and convincing results are available.
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